Application Note: Mutation Detection in Circulating Tumor Cell Samples Obtained from the IsoFlux™ System
21 June 2013

Cancer progression in humans stems from acquired DNA mutations in a specific group of cells. While the causes of these mutations are still not fully understood, their role in malignancy has become evident. As such, the detection of mutations in cancer causing oncogenes has become increasingly important in the clinical management of disease. Circulating tumor cells (CTCs) have shown great promise to offer longitudinal insight to metastatic disease. CTCs can be obtained from a simple blood draw that overcomes previously mentioned challenges in obtaining tissue specimens. In this application note read about a novel KRAS mutation detection assay that can be run on CTCs obtained from the IsoFlux System.